MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
about
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewThe copper chelator ATN-224 induces caspase-independent cell death in diffuse large B cell lymphomaThe sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activityEpstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infectionPI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications.Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1Diffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing.Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma.An evidence-based review of obatoclax mesylate in the treatment of hematological malignanciesLow dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2-naphthoates as selective inhibitors of the Mcl-1 oncoprotein.PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?Regulation of hematopoietic stem cell integrity through p53 and its related factors.Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.Survival control of malignant lymphocytes by anti-apoptotic MCL-1.Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphomaGene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB.Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells.Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.Intracellular BH3 Profiling Reveals Shifts in Antiapoptotic Dependency in Human B Cell Maturation and Mitogen-Stimulated Proliferation.Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development.Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain.The molecular pathogenesis of mantle cell lymphoma.Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
P2860
Q27304386-61BE32F2-CF34-4618-AAF6-5E810EE3F452Q28389285-6D6DEECC-F25C-452F-AA0F-2AA7C9ED6E94Q28487756-37D1BE2A-62DA-44D3-9648-EDFAE004C8E4Q33658144-24D870B9-5BF5-479A-99D5-5A3DBC029BDBQ34199935-1AEA968A-3EF0-413E-8C66-FCA2680DE12EQ35818443-9C341BD3-DB99-4B13-B919-F66335841F77Q35920657-C8CF2DD7-0A07-4DF7-88B3-D9D87B4E62E2Q36210487-851EE281-C997-440A-B8B8-8EC7C848224FQ36544524-3E8901FD-5F74-4C22-BFD4-B2C4360C93E3Q36696524-CBB82395-64F4-4D48-B5EB-3215AD16CB3FQ36725307-930B6745-049F-4D29-A59D-6651E29C67AAQ36739519-7C4047B3-62BB-450A-90A5-D972900E67A0Q37049376-815FBE06-0A24-4983-BA01-D4958E1DAEFDQ38193997-05DA9492-4D24-46A3-B567-0025E71867A9Q38676677-20B977E5-2264-4142-8546-3C1C3EAC6CFCQ38906418-9022852C-D46C-4208-860B-744A47FFB032Q38914858-AD52FFE0-CAF9-4F63-AC5D-8C94D421B015Q39267135-3B42FA6F-2E08-4611-82A6-83E130EA34D5Q39926284-EC9B75BA-AA9C-4F57-B4CD-772669F81D6EQ43963203-774341D9-CEE8-44D0-99DE-08D7B821D10CQ45301087-AEF9CB27-7D76-4595-8AE6-16382B1AC2C0Q47130049-E4B45E31-6E46-40E6-AD35-D1DA2F676AF9Q47550209-A97CCFFD-E4B1-452F-99E1-D6C3A29DD3FBQ48222343-C62F8E44-0B7C-4464-B1B8-AB93A7BA285EQ50105551-A12C3DFC-27A9-4403-9549-6D6F1FCCC939Q51533605-B48FF72D-FC2F-43A9-A4EB-F50DA59DDAC7Q55007581-3D823129-6D05-43BB-83BF-003B33908602Q55455226-C4A12F2C-3C98-412C-9ECE-D47DF99C2F32
P2860
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
@en
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
@nl
type
label
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
@en
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
@nl
prefLabel
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
@en
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma
@en
P2093
F J Hernandez-Ilizaliturri
S Dirnhofer
S Hailfinger
P2860
P2888
P304
P356
10.1038/LEU.2012.367
P577
2012-12-21T00:00:00Z